- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07714239
Pharmacist-Assisted Titration of Rx to Implement Optimal Medical Therapy for Heart Failure (PATRIOT-HF)
Pharmacist-Assisted Titration of Rx to Implement Optimal Medical Therapy for Heart Failure (PATRIOT-HF) (QUE 25-018)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Heart failure with reduced ejection fraction (HFrEF) affects a large proportion of Veterans and isa leading cause of hospitalization and death. Clinical guidelines recommend four classes of medications (commonly called "quadruple therapy") that improve survival and reduce hospitalizations, yet 42% of Veterans hospitalized with heart failure do not receive all recommended medications at discharge.
This study implements a virtual pharmacist and cardiologist team (hub) that provides digital consultation to hospitalists and primary care providers (spoke) at VA medical centers regarding use of guideline-directed medical therapy (GDMT) during hospitalization and the post-discharge period. The pharmacist/cardiologist team identifies eligible Veterans using a VA hospital-specific dashboard, reviews electronic health records, and places digital consultation notes with individualized medication recommendations, safety surveillance information, and out-of-pocket medication cost data.
The intervention also incorporates identification of Veterans hospitalized in VA-paid community care settings. Veterans hospitalized with heart failure in community hospitals within the preceding 3 months are identified via VA-paid community care claims data, and actionable recommendations are provided through the VA electronic health record or by facsimile to community providers.
Six VA medical centers served by Clinical Resource Hubs in VISNs 4, 16, 17, 19, and 23 are participating. Sites are randomized to one of three implementation waves in a cluster-randomized stepped-wedge design, with implementation occurring every 6 months at two sites per wave. This design allows estimation of intervention effects using both within- and between-site comparisons while controlling for secular trends. A difference-in-differences analytic approach with covariate-constrained randomization is used to estimate causal effects.
The primary effectiveness outcome is change in GDMT optimization score from admission to 14 days after discharge. Secondary effectiveness/safety outcomes include mortality, heart failure readmission, and medication-related adverse events at 90 days. Implementation outcomes are assessed using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework and include fidelity to identification of at-risk Veterans, provision of recommendations,, outpatient follow-up rates, and barriers and facilitators to implementation Additional outcomes derived from the RE-AIM framework will also be captured.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Paul L Hess, MD MS
- Telefoonnummer: (720) 857-6889
- E-mail: paul.hess@va.gov
Studie Contact Back-up
- Naam: Lexus L Ujano-De Motta, BS
- Telefoonnummer: (808) 990-3993
- E-mail: lexus.ujano-demotta@va.gov
Studie Locaties
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045-7211
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
Contact:
- Paul L Hess, MD MS
- Telefoonnummer: (720) 857-6889
- E-mail: paul.hess@va.gov
-
Hoofdonderzoeker:
- Paul L Hess, MD MS
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
Admission to a VA medical center or VA-paid community hospital within the preceding 3 months with a primary diagnosis of heart failure
- The primary study cohort will consist of those admitted to a VA medical center, while the secondary study cohort will consist of patients admitted to VA-paid community hospitals
- Left ventricular ejection fraction ≤ 40%
- Not on optimal guideline-directed heart failure medication classes or doses, as assessed in the electronic health record
- Receiving care within one of the 6 participating VA medical centers
Exclusion Criteria:
- Hemodynamic instability
- Receiving comfort care measures alone or enrolled in hospice
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Pharmacist/Cardiologist Virtual Team (Intervention)
VA medical centers randomized to the active intervention period receive digital consultation from a centralized pharmacist and cardiologist virtual team regarding guideline-directed medical therapy for hospitalized Veterans with heart failure and during the post-discharge period.
The intervention includes identification of eligible Veterans, placement of digital consultation notes in the EHR, facilitation of outpatient follow-up, and Veteran education.
|
A centralized pharmacist and cardiologist virtual team (hub) provides protocol-based digital consultation notes to inpatient and outpatient providers(spoke) regarding initiation and intensification of guideline-directed medical therapy (GDMT) for heart failure during hospitalization and the post-discharge transitional care period.
Eligible Veterans are identified via VA dashboards and community care claims data.
Recommendations cover quadruple therapy (beta blockers, ACEI/ARB/ARNI, MRA, SGLT2i) and are tailored to individual clinical presentations.
The pharmacist arranges outpatient follow-up and delivers medication adherence education.
Andere namen:
|
|
Geen tussenkomst: Usual Care (Control Period)
VA medical centers during their pre-implementation (control) period provide usual care for Veterans hospitalized with heart failure without input from the pharmacist/cardiologist virtual team.
In the stepped-wedge design, all sites eventually cross over to the intervention arm.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Guideline-Directed Medical Therapy (GDMT) Optimization Score
Tijdsspanne: From hospital admission (baseline) to 14 days after discharge (VA direct care) or 14 days after Veteran eligibility identification (VA community care)
|
The GDMT Optimization Score reflects the proportion of eligible guideline-recommended heart failure medications prescribed relative to the total for which the Veteran is eligible.
Points are assigned as follows - Numerator: ACEI/ARB=1, ARNI=2, evidence-based beta blocker=2, MRA=2, SGLT2i=2, Vericiguat=1, Ivabradine=1, Hydralazine/Nitrates=1. Denominator reflects eligibility for each class.
A higher score indicates greater concordance with guidelines.
|
From hospital admission (baseline) to 14 days after discharge (VA direct care) or 14 days after Veteran eligibility identification (VA community care)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in NIH Heart Failure Collaboratory Score
Tijdsspanne: From hospital admission (baseline) to 14 days after discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
A composite GDMT metric assessing the breadth and completeness of guideline-recommended heart failure pharmacotherapy.
|
From hospital admission (baseline) to 14 days after discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
|
All-cause mortality
Tijdsspanne: 30 days and 90 days after hospital discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
Death from any cause, ascertained from the VA Death Ascertainment File.
|
30 days and 90 days after hospital discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
|
Heart Failure Readmission
Tijdsspanne: 30 days and 90 days after hospital discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
A claim for inpatient admission with any HF diagnosis on the claim, ascertained from the VA Corporate Data Warehouse and Consolidated Data Set.
|
30 days and 90 days after hospital discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
|
Medication-related adverse outcomes - acute kidney injury
Tijdsspanne: 90 days after hospital discharge or Veteran eligibility identification
|
Acute kidney injury identified by creatinine levels and ICD diagnostic codes in the VA Corporate Data Warehouse.
|
90 days after hospital discharge or Veteran eligibility identification
|
|
Medication-related adverse outcomes - bradycardia
Tijdsspanne: 90 after hospital discharge or Veteran eligibility identification
|
Bradycardia identified by vital sign readings and ICD diagnostic codes in the VA Corporate Data Warehouse.
|
90 after hospital discharge or Veteran eligibility identification
|
|
Medication-related adverse outcomes - hyperkalemia
Tijdsspanne: 90 days after hospital discharge or Veteran eligibility identification
|
Hyperkalemia identified by potassium laboratory values and ICD diagnostic codes in the VA Corporate Data Warehouse.
|
90 days after hospital discharge or Veteran eligibility identification
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Paul L Hess, MD MS, Rocky Mountain Regional VA Medical Center, Aurora, CO
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- QUX 26-006 (VA Quality Enhancement Research Initiative (QUERI))
- QUE 25-018 (Ander subsidie-/financieringsnummer: VA Quality Enhancement Research Initiative (QUERI))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .